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Abstract
Background: A relative inability to capture a sufficiently large patient population in any one geographic location
has traditionally limited research into rare diseases.
Methods and Results: Clinicians interested in the rare disease lymphangioleiomyomatosis (LAM) have worked
with the LAM Treatment Alliance, the MIT Media Lab, and Clozure Associates to cooperate in the design of a
state-of-the-art data coordination platform that can be used for clinical trials and other research focused on
the global LAM patient population. This platform is a component of a set of web-based resources, including a
patient self-report data portal, aimed at accelerating research in rare diseases in a rigorous fashion.
Conclusions: Collaboration between clinicians, researchers, advocacy groups, and patients can create essential
community resource infrastructure to accelerate rare disease research. The International LAM Registry is an
example of such an effort.
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A relative inability to capture data concerning asufficiently large patient population in any one geogra-
phic location has traditionally limited insight into rare dis-
eases and complicated clinical trial design. To overcome this
challenge, clinicians and researchers interested in lymphan-
gioleiomyomatosis (LAM) from around the world worked
with the LAM Treatment Alliance 501(c)(3), the MIT Media
Lab, and Clozure Associates to cooperate on the design of a
state-of-the-art encrypted web-based International LAM
Registry that can be used for clinical trials and other research
focused on the global LAM patient population. The Interna-
tional LAM Registry (ILR) is a component of a set of web-
based resources, including a patient self-report data portal,
aimed at accelerating research in rare diseases in a rigorous
fashion. The ILR is due to launch with a discrete first project
in 2010.
LAM is a rare multisystem disease affecting almost exclu-
sively women, predominantly in their child-bearing years.
The disease is characterized by the proliferation of abnormal
smooth muscle-like cells that are associated with the forma-
tion of lung cysts andmicroscopic nodules, cystic structures in
the axial lymphatics, and renal angiomyolipomas.1–6 LAM
occurs in approximately one-third of womenwith the heritable
genetic disorder Tuberous Sclerosis Complex.7–10 Sporadic
LAM is much rarer, with an incidence of 2.6 cases per million
women aged 20–69 years, although a significant proportion of
women with LAM may be undiagnosed.6 While the disease is
variable in its presentation and course, its most morbid impact
is on the lungs, and progressive respiratory compromise may
lead to death.2,3,6
There are no effective treatments for LAM. Lung trans-
plantation is the only known life-prolonging therapy.11
LAM, however, can reoccur in the new graft, and genetic
analysis of these cases suggests a metastatic basis for the
disease.12,13
Progress in cancer biology and research in both LAM and
TSC yielded several potential molecular targets for this dis-
ease.14 The ongoing Multicenter International LAM Efficacy
of Sirolimus Trial (trial registration identifier, NCT00414648,
Frank McCormack PI) is currently investigating the effects of
the mTOR inhibitor sirolimus in pulmonary LAM. In addi-
tion, a placebo-controlled trial investigating the effects of
doxycycline is underway in the United Kingdom (EUDRACT
registration 2007-003745-32, Simon Johnson, PI).
Objectives
The International LAM Registry has the following
objectives:
1. To accelerate research towards a treatment;
2. To provide scientists, clinicians, and patients with ac-
cess to a state-of-the-art data coordination platform that
can be used for clinical trials and other research focused
on the global LAM patient population;
3. To enhance the understanding of the variability, pro-
gression, and natural history of LAM.
Towards these ends the registry will:
1. Create, reinforce, and expand a network of cooperating
LAM clinician researchers and basic scientists;
2. Build clinical trials data and technology coordination
functions into the online platform:
3. Increase access to harmonized clinical data by clinicians
and researchers around the world;
4. Create a mechanism to address discrete scientific ques-
tions that would be difficult to answer without access to
a global patient population;
5. Provide patients with access to:
a. A site for ascertaining their willingness to have
their treating clinicians contacted for future trials;
b. Their own clinical information;
c. A centralized location for providing consent;
d. A portal to update their contact information to
enable long-term tracking;
e. Web-based questionnaire surveys to improve cli-
nician, patient, and researcher communication and
simplify data collection.
Concept, History, and Funding
The LAM Treatment Alliance (LTA), a nonprofit 501(c)(3)
organization focused on aggressively driving and funding
research towards a treatment for LAM, conceptualized and
funded the ILR by entering into a strategic partnership with
the MIT Media Laboratory. The MIT Media Lab’s research
seeks to envision and explore the impact of emerging tech-
nologies on society. Researchers are developing technolo-
gies to support new forms of collaboration among doctors,
patients, clinicians, and researchers with a specific emphasis
on the problems encountered in rare disease communities.
The ILR is one component of a set of web-based tools, in-
cluding a patient self-report data portal (LAMsight) that, with
patient consent, can be linked to create a robust record of de-
identified data for each subject. These tools are aimed at
accelerating research in rare diseases in a rigorous fashion.
They are part of a vision that engages patients as valuable
participants in the research process.
Previous registry initiatives have failed to achieve high
levels of patient and data accrual due to the time-consuming
nature of data entry and poor perception of benefit to indi-
vidual researchers. To address these issues, the ILR’s organi-
zation is focusing on maximizing incentives to participation.
Philosophically, the ILR seeks to ensure that raw patient data
are available as a community resource which allows scientists
to compete for insight into LAM while ensuring that de-
identified patient data remains in the public domain.
There are multiple incentives for participation. The most
important envisaged incentive is providing simple coordi-
nated access to clinical trials. In addition, the ILR will provide
access to data from the global LAM patient population esti-
mated at between 1000—2000 subjects by report of interested
clinicians, allow complete freedom to publish one’s own data
at any time, provide for clinician inclusion on ILR publica-
tions in an appendix to all articles, include the option for cli-
nicians to become authors or refuse use of their own data if a
study uses more than 20% of patients from one’s Center, and
permit clinician and researcher access to an easy, secure data
management platform with technical support at no cost.
Conventional views of data gathering hold that a discrete
question should be identified in a hypothesis testing fashion
and that data should be gathered to solely address the specific
question. While this approach is entirely valid, enquiry of
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large data sets have also yielded novel insights into disease
processes.15 Initially, the ILR will emphasize the hypothesis-
testing approach to facilitate collaborations and to improve
the data management platform. The long-term goals for the
ILR are clinical trials coordination and a data repository used
to test for novel and unpredicted associations and insights
into LAM and other rare diseases. For this reason, the plat-
form was conceptualized and designed to handle and har-
monize large volumes of data. The ILR platform will have
many of the features required for data management and ad-
ministration that anticipate the challenges of undertaking
clinical trials for a rare disease. A given trial often replicates
effort that may include patient recruitment, datamanagement
facilities, multisite coordination protocols, and the trial design
itself. A common platform for LAM clinical trials could sig-
nificantly lower the activation energy required to initiate
new trials, improve intra-trial coordination, and provide a
clear point of contact for long-term patient engagement both
through and independent of a given clinic.
Through the collaboration with the MIT Media Labora-
tory, novel capabilities for the registry will be designed that
help to simplify patient recruitment, support harmonization
of data across sites, automate event and other regulatory
reporting, data safety monitoring, and analysis and visuali-
zation of the ongoing trial data (where approved by a trial
protocol).
Companion portal: LAMsight
LAMsight (www.lamsight.org) is an online portal being
developed contemporaneously to the ILR.16 The website is
an interactive community that allows patients to enter self-
reported data in a de-identified fashion. With appropriate
regulatory approval, researchers can place questionnaires and
surveys on LAMsight. In future iterations of the platform
being designed for LAM, patients will be able to consent to
have their de-identified LAMsight data linked to their clini-
cian entered de-identified ILR data. As future portals are
developed (tissue, or genomic portals), with appropriate
regulatory approval, de-identified data from these will be
linkable, creating a robust research tool. Data entered into
LAMsight are always labeled as self-reported and clearly
distinguished from clinician-entered ILR data.
International LAM Registry Governance, Rules,
and Rationale
The ILR will be governed by a Scientific Committee mod-
eled on a journal peer review board. Peer review of all ap-
plications that make use of the ILR will be undertaken by the
Scientific Committee which is comprised of independent and
accomplished non-LAM clinicians and scientists, LAM ex-
perts, a patient with sophisticated insight into LAM, and an
expert in human subjects oversight and regulatory affairs.
Rules for participation in the ILR appear in Appendix 1. The
rules were designed with a view to being inclusive while
providing participation incentives for those clinicians enter-
ing the most patients. Several mechanisms were created to
ensure these aims. Although any clinician seeing LAM pa-
tients can participate in the ILR, to be considered a ‘‘Colla-
borator,’’ an individual clinician is required to enter at least
five patients. Collaborators are then named in the appendix to
all scientific publications that use ILR data. This rule ensures a
minimum contribution before the rewards from participating
are received.
If any manuscript includes data from more than 20% of
patients from a single participating clinician, then this clini-
cian must consent to the use of his=her patients in the study
and be given the opportunity to co-author or refuse the in-
clusion of his=her patients. This rule is designed to ensure
that significant contribution to the ILR is rewarded and not
exploited.
The ILR recognizes that there is an inherent tension be-
tween the desire to ensure that data are maximally accessible
and in the public domain and the need to protect contributors
from having their data used without reward. To resolve these
conflicting interests, anyone with appropriate skills can make
a request to use the ILR data for research, priority however is
given to contributors. The Scientific Committee of the ILRwill
be the arbiter of these decisions.
The ILR seeks to facilitate research while at the same time
ensure appropriate human subject protections. To facilitate
research, interested investigators will be able to request a
feasibility query from the Scientific Committee to determine
whether there are sufficient data to address one or more
specific questions. The query can take place prior to gaining
local human subjects review board (e.g., IRB or Ethics Com-
mittee) approval. If the feasibility query is favorable, then the
investigator will be able to apply for human subjects approval
and on documentation of this, raw data from the query are
provided. Several ILR rules were created anticipating future
ILR functions. These may include the potential to link a sub-
ject’s ILR data to tissue and specimen data, to data that a
patient can self-report, or to genomic data. By providing pa-
tients with a portal to self-report data that are linked to the
ILR, clinicians and scientists will be able to perform survey
studies of patients and have the responses linked to the ILR,
subject to appropriate regulatory approval. The ILR platform
is not able to perform these functions currently and if col-
laborators decide that these functions will be useful, patients
will be permitted to create the linkage with appropriate in-
formed consent procedures in place.
Quality Control and Validation
Data will be regularly controlled for quality and prior to
entering data into the ILR, participants are required to pro-
vide information which permits assessment and analysis of
data quality, integrity, and provenance for the data they
provide. Given the known variability in Pulmonary Function
Testing (PFT) and their current importance in measuring
LAM progression and response to treatment, Centers will be
required to report on the level of quality control that they
employ. Data from eachCenter will be assigned a quality level
based on a range of quality markers including but not limited
to compliance with standardized criteria for calibration and
performance of tests, the ATS= ERS pulmonary function test-
ing recommendations, and for individual tests, a review of at
least three de-identified blows by a spirometry expert.
In addition to self reporting, the ILR will appoint a quality
control officer, a non-LAM pulmonologist, who will visit a
selection of participating Centers on an annual basis to ob-
serve testing and quality control procedures. During this visit,
the quality control officer will request a random selection
of patient medical records entered from that Center and a
THE INTERNATIONAL LAM REGISTRY 83
portion of the data from those records will be re-entered into
the ILR as a test of data accuracy and provenance. The officer
will submit an annual report and recommendations to the
Scientific Committee.
Data from Centers not found to meet the self-reported
standard will have their quality label adjusted accordingly.
ILR participants agree to facilitate access of the quality control
officer to the Center’s Pulmonary Function Test laboratory,
and medical records. Centers will be provided with a copy of
their report. This information will not be made available to
other ILR participants.
Organization
The International LAM Registry provides a browser-based
application that enables the entry, aggregation, query, re-
porting, and export of clinical patient data to and from a
centralized database. The description here captures the in-
tended final form of the site and while many of these features
have been implemented or prototyped, the final version of the
site may differ in some respects as development proceeds and
user feedback is accommodated.
The ILR’s web-based interface is divided into a collection of
modules that serve different functions and can be enabled or
disabled to support different classes of users.
 Viewer: the data viewer provides an overview of a
subset of patients in the database. Individual patient
forms and data can be viewed and links are provided to
the data entry module.
 Entry: the entry module facilitates the entry of data from
clinical sites and registries worldwide. It provides a
compact view of one or more forms. Special support is
provided to handle the unique issues of provenance and
harmonization across different sites and countries as
described below.
 Query and Analysis: this module allows a user to sub-
mit queries to the database to retrieve field data for a
subset of patient records. The query system further
supports query refinement based on data provenance
and privilege. It can provide direct or aggregated views
of the data. Basic statistical tools and data visualization
features are provided to characterize aggregated query
results.
 Dataset review: the system records the results of ap-
proved queries and makes them available to the re-
quester, if the requester has an account on the system. A
record of query results and exported datasets are
maintained for future download and review.
 The system supports multiple user account types to
customize the site interface for the diverse rights and
needs of clinicians, data entry personnel, researchers,
individual patients, site curators, and site administra-
tors. Each account type will have access to a specific
subset of the system’s modules and data (Appendix 2).
The ILR’s database supports a wide variety of records and
can be easily extended to accommodate new data types, such
as blood tests, or content types such as CT scans. The primary
data storage is a highly flexible schema for defining forms,
each of which contains a sequence of, potentially complex,
data fields. There are a large number of field types to support
different data formats and layouts (such as numbers, mea-
surements, dates, and fixed rating scales). Each data entry
associates a data value for a given field with a unique patient
ID in the database. The interface can provide different views
of the forms, fields, and data for different users and purposes.
Technical Challenges and Solutions
Creating infrastructure to support multiple sites inmultiple
countries presents a variety of specific design challenges for
the ILR. Specific features and technologies are introduced to
address each of the major challenges.
The site employs an object-oriented database architec-
ture.17 This approach provides a highly flexible, and powerful
query system, reducing the cost of making changes to the
system over time. The design of the records supports the rapid
creation and evolution of forms and fields to support different
sites or different trials. A consequence of this facility is that
data for a given patient may be recorded on different forms,
while representing a common parameter (e.g., PFTs), that
may be valuable in the course of an ILR query. A given field
can be marked as being able to be harmonized with fields in
other forms.
These and other relationships among data lead to poten-
tially very complex provenance. Data may have been subject
to different collection conditions or there may be multiple
interviewers recording patient history. Data may be edited
or updated over time. To enable query and analysis in the
presence of these complex relationships, the database main-
tains a complete history and provenance of all database
entries including date, individual who entered the data,
originating site, and any additional necessary annotations.
Data harmonization is a significant challenge that arises
when aggregating data across multiple sites. To adequately
capture subtle differences between question phrasing or mea-
surement procedure, the database provides support for per-
answer annotations that record characteristics of the entered
data. For ease of entry, pre-defined annotations can be se-
lected from a drop-down control during data entry. Specific
sites can set defaults to simplify data entry overhead. As
with data provenance, additional annotations can be associ-
ated with a data field as required, such as whether patients
have the ability to access particular forms or fields in their
records.
Electronic security is ensured through several means. The
HTTPS browser protocol used to secure most web-based
electronic transactions is employed to encrypt data flowing
to and from the ILR. Access to the ILR is enabled by a unique
username and a password assigned to each user. Each user
is assigned to a specific role category on the site by the Sci-
entific Committee. A password policy is instituted that en-
sures the strength of the password and encourages regular
updating. All data that are backed-up off-site are encrypted
by a public-key encryption protocol that will ultimately be
under control of the Scientific Committee.
One of the goals of the ILR is to enable long-term tracking of
LAM patients by motivating patient involvement and self-
report. Scenarios where this would be useful include, but are
not limited to, information about patients who havemoved to
new clinics, de-duplication of patient records and tracking
patients that have stopped seeing their treating clinicians.
Updates over time and long-term tracking may be supported
in two ways:
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1. Patients can be provided their unique ID to log into the
ILR to review and print their own clinical records. Pa-
tients can provide their electronic mail (e-mail) address
in order to be contacted in the future for trials or to
check on their current status.
2. Patients can participate in the companion, patient-
oriented site LAMsight and their unique account there
can be related to their ILR unique ID.
The availability of records and access to information about
LAM provide incentive for individual patients to access these
resources and to provide their e-mail address. The ILR and
LAMsight both make the e-mail address invisible to all users.
However, a clinician, a researcher, or the site curator can send
an e-mail to users by using their unique ID. The system will
map from the unique ID to the e-mail address anonymously,
e-mail the user via an encrypted mail server interface, and
record this interaction. The site can be enabled to allow pa-
tients to review their record and to initiate a query to both their
treating clinician and site curator regarding data entered un-
der their identifier that they believe to be inaccurate. Patients
will have the ability to validate their own record in a similar
fashion.
Regulatory and Ethical Concerns
Recognizing the diverse requirements for performing
human subjects research throughout the world, the ILR rules
require that researchers using the ILR demonstrate the receipt
of local regulatory approval to participate in data entry and
undertake research. In addition, the ILR has received ap-
proval for use at the corresponding author’s institution by the
Partners Human Research Committee and is subject to con-
tinuous review from this body. Sample institutional review
board, ethics, and individual patient consent forms are made
available to participants in order to minimize the necessary
effort in acquiring approval.
When adding a new patient to the ILR, clinicians are en-
couraged but not required to enter the patient’s name and
date of birth. These data are not retained, and are used to
create a unique one-way hash,18 or identifier, for the patient
which prevents duplicate records from being created if the
same patient is seen at multiple Centers. This information is
kept in a secure part of the site to which users do not have
access and which cannot be used to directly identify patients.
A separate ID is issued to the clinician for that patient for all
subsequent data entry. These procedures minimize the stor-
age of personal identifiers in the actual dataset as specified by
US standards on healthcare privacy as currently defined by
the Health Insurance Portability and Accountability Act of
1996 (HIPAA).19
Where there is a compelling reason to store personal iden-
tifiers such as examination and diagnosis dates at a resolution
more accurate than a year, or treating clinic and physician,
these fields are marked as identifiers that can be automatically
excluded from queries, resulting in fully de-identified datasets.
A mapping between patient names and unique IDs may be
maintained on physical media by the Scientific Committee for
purposes of data recovery in the event a clinic loses the map-
ping or, for example, if a patient is requesting access to the
records directly.
The ILR institutes procedural controls that complete these
technical capabilities. All users will be validated and ap-
proved by the Scientific Committee. Only the site curator and
administrator have access to the entire database and use of
this interface must be approved by the Scientific Committee.
Finally, for technical support and other uses, the ILR
maintains a record of user account access to the site and as-
sociated information such as the IP address of the requests.
The site maintains these identifiers in the system log for the
duration of a week and then expunges them from the system.
Future Functionalities
The ILR is currently focused on the essential issues of data
capture, data quality, security, privacy, and governance. The
ILR is being designed to be an integrated data management
portal aimed at coordinating clinical trials. The ILR is a com-
ponent of a set of web-based tools that, with patient consent,
will be linked to create a robust record of de-identified data for
each subject. Specific functions that may be added in the fu-
ture include:
 Direct patient–researcher interaction modules designed
to support questionnaires and other studies using in-
struments such as home peak flow meters that can re-
cord information electronically and upload to the site.
 A comprehensive tissue program module to further in-
tegrate global patient data and specimen resources by
creating a centralized location for consent and allowing
linkage between clinical, research, and tissue data.
 Genetic information including germline and somatic
mutations in candidate causative genes, polymorphisms
in candidate susceptibility genes, and genome-wide
DNA, RNA, microRNA, and proteomic analyses.
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Appendix 1. International LAM Registry (ILR) Rules
1. The LAMTreatmentAlliance (LTA)will fund the ILR as a service
to the global LAM community on a renewable basis provided
that the ILRadheres to its statedobjectives, rules, andregulations.
Aminimum requirement is that the ILR remains transparent and
accountable in its process and that the interests of the global LAM
community, patients in particular, are put first.
2. Peer review and governance will be conducted by a Scientific
Committee comprised of independent and accomplished non-
LAM clinicians and scientists, LAM experts, a patient with
sophisticated insight into LAM, and an expert in human
subjects oversight and regulatory affairs. The Committee will
be created by The LAM Treatment Alliance and a represen-
tative of LTA will sit on the Committee. The Committee will
review and approve all applications to make use of the ILR
data within one month of application. Decisions will be based
upon scientific merit and the pre-stated goals of the ILR. Other
considerations will include potential duplication of proposed
projects, resource utilization, and legal, regulatory, and ethical
concerns. The Committee will have the right to send proposals
to domain-specific experts for review.
3. Participants are required to have enrolled a minimum of 5
patients to gain access as an ILR ‘‘collaborator’’.
4. Clinicians being provided with or collecting data from col-
leagues in smaller Centers are encouraged to publish these data
independent of the ILR and with their colleagues from small
Centers as co-authors. This provision is intended as an academic
incentive to smaller Centers to provide their data to the ILR.
5. Upon patient request, clinicians will provide an individual
patient their unique identifier for the ILR portal. This will al-
low patients to see, but not modify their own clinical data on
the ILR portal. Patients will not have access to their research
data. In addition, patients will be allowed to link their ILR
data with self reported data entered through a different portal
on the ILR or LAM site. Self-reported data will always be
clearly coded as self-reported.
6. Any health care provider or scientific researcher may generate
proposals to publish aggregate data.
7. The publication policy that follows does not apply to site-
specific data and, as such, clinicians are free to publish their
own data at any time.
8. ILR collaborators, health care providers, or researchers inter-
ested in publishing ILR data must submit their proposal for
publication and request for data analyses on the standardized
registry form.
9. ILR collaborators, health care providers, or researchers can
submit a request to the Scientific Committee for a feasibility
analysis on a particular question in which they are interested.
The standardized form must be used. A feasibility response
will be returned within one month of application. Full data on
the question will only be provided after the Scientific Com-
mittee has approved the request and proof of IRB approval to
perform the study is provided.
10. Abstracts and manuscripts generated from pooled ILR data
must be reviewed and approved by the Scientific Committee
prior to submission for use in any public format. Review will
take place within one month of submission.
11. If the data set used for the analysis is comprised in-total of
more than 20% of patients from a single contributing physi-
cian, that contributing physician should consent to the publi-
cation and be invited to co-author provided his or her
contribution is consistent with authorship criteria as described
by the International Committee of Medical Journal Editors.
The principal author will discuss the project and authorship
directly with the contributing physician. The contributing
physician will have the option to withdraw his or her data
from this publication.
12. The International LAM Registry must be cited as an author on
any publication; ILR collaborators will be listed in an appen-
dix to the manuscript.
13. Manuscripts generated from registry data are required to
comply with the International Committee of Medical Journal
Editor’s requirements.
14. The International LAM Registry must be appropriately ac-
knowledged as the source of all data. Funding sources for
research and the ILR must be acknowledged in order of
Funding significance. In addition, proper acknowledgement
must also be given to those non-authors who contributed to
the data analyzed.
15. This policy does not apply to requests for ILR data for the
purposes of clinical interest or individual patient care pro-
vided that such data will not be presented in a public forum.
Such requests will be addressed expeditiously and ideally
within two weeks of receipt.
16. ILR data will be regularly validated.
17. Standards of data quality will be established by the Scientific
Committee; ILR data will be labeled in accordance with its
known provenance and quality.
18. In order to ensure that patients who are seen at multiple
Centers are not entered under different identifiers, the ILR will
encourage, but does not require, that each patient’s name and
date of birth are entered. This information will only be avail-
able to generate a unique identifier for each patient.
Appendix 2. International LAM Registry Access Levels
 Clinician: Clinicians will have access to the full records of their
own patients as well as the results of any approved queries run
on their behalf and the resulting anonymized or aggregated da-
tasets. Clinicians will be able to add new patients and edit the
records of their existing patients. In addition, clinicians will have
a basic query interface to search the records of their own patients.
 Data entry personnel: Data entry personnel will have access to
de-identified patient records in order to add, edit, or update
patient data.
 Researcher: A researcher account provides access to approved
query results and aggregated data sets that can be downloaded
from the website, but provides no access to a specific patient’s
clinical records.
 Patient: The system can be modified so that a patient can be
given access to an account that provides a read-only view of
their own clinical data via the data viewer modules. Not all
fields are necessarily visible as information collected and stored
as part of a trial may not be appropriate to expose to the indi-
vidual patient.
 Site curator: The site curator is responsible for maintaining
the content of the site, adding and maintaining user ac-
counts, and managing the clinical data fields and record
definitions for clinical data. The curator runs data queries
and analyses for all requests approved by the committee. The
curator will also then make data available to specific clinician
or researcher accounts.
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